Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $176 from $171 and keeps an Equal Weight rating on the shares. The firm cites the company’s Q2 earnings beat and expectations for top and bottom line growth in 2026 but also notes limited visibility on potential pharma tariffs and Most Favored Nation drug pricing policy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson delivered ‘solid’ Q2, says Wells Fargo
- Johnson & Johnson’s Earnings Call Highlights Growth and Challenges
- Johnson & Johnson’s Strong Financial Performance and Strategic Positioning Justifies Buy Rating
- Cautious Optimism: Johnson & Johnson’s Strong Performance and Future Prospects Amid Legal Uncertainties
- Johnson & Johnson: Hold Rating Amid Mixed Signals and Uncertainties